These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 20694797)
1. Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy. Pachmann K; Camara O; Kohlhase A; Rabenstein C; Kroll T; Runnebaum IB; Hoeffken K J Cancer Res Clin Oncol; 2011 May; 137(5):821-8. PubMed ID: 20694797 [TBL] [Abstract][Full Text] [Related]
2. An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer. Pachmann K; Dengler R; Lobodasch K; Fröhlich F; Kroll T; Rengsberger M; Schubert R; Pachmann U J Cancer Res Clin Oncol; 2008 Jan; 134(1):59-65. PubMed ID: 17611779 [TBL] [Abstract][Full Text] [Related]
3. Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma. Pachmann K; Camara O; Kroll T; Gajda M; Gellner AK; Wotschadlo J; Runnebaum IB J Cancer Res Clin Oncol; 2011 Sep; 137(9):1317-27. PubMed ID: 21739182 [TBL] [Abstract][Full Text] [Related]
4. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Camara O; Rengsberger M; Egbe A; Koch A; Gajda M; Hammer U; Jörke C; Rabenstein C; Untch M; Pachmann K Ann Oncol; 2007 Sep; 18(9):1484-92. PubMed ID: 17761704 [TBL] [Abstract][Full Text] [Related]
5. Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer. Mäurer M; Schott D; Pizon M; Drozdz S; Wendt T; Wittig A; Pachmann K Curr Oncol; 2022 Dec; 30(1):261-273. PubMed ID: 36661670 [TBL] [Abstract][Full Text] [Related]
6. Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment. Camara O; Jörke C; Hammer U; Egbe A; Rabenstein C; Runnebaum IB; Hoeffken K; Pachmann K J Cancer Res Clin Oncol; 2009 Apr; 135(4):643-7. PubMed ID: 18936973 [TBL] [Abstract][Full Text] [Related]
7. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. Pachmann K; Camara O; Kavallaris A; Krauspe S; Malarski N; Gajda M; Kroll T; Jörke C; Hammer U; Altendorf-Hofmann A; Rabenstein C; Pachmann U; Runnebaum I; Höffken K J Clin Oncol; 2008 Mar; 26(8):1208-15. PubMed ID: 18323545 [TBL] [Abstract][Full Text] [Related]
8. Demasking of epithelial cell adhesion molecule (EpCAM) on circulating epithelial tumor cells by Tween®20 treatment in breast cancer patients. Hekimian K; Stein EL; Pachmann U; Pachmann K Clin Chem Lab Med; 2012 Dec; 50(4):701-8. PubMed ID: 22505561 [TBL] [Abstract][Full Text] [Related]
9. Circulating epithelial tumor cells as a prognostic tool for malignant melanoma. Pachmann K; Willecke-Hochmuth R; Schneider K; Kaatz M Melanoma Res; 2018 Feb; 28(1):37-43. PubMed ID: 29076925 [TBL] [Abstract][Full Text] [Related]
10. Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse. Lobodasch K; Fröhlich F; Rengsberger M; Schubert R; Dengler R; Pachmann U; Pachmann K Breast; 2007 Apr; 16(2):211-8. PubMed ID: 17291754 [TBL] [Abstract][Full Text] [Related]
11. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
12. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143 [TBL] [Abstract][Full Text] [Related]
13. Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer. Mignot F; Loirat D; Dureau S; Bataillon G; Caly M; Vincent-Salomon A; Berger F; Fourquet A; Pierga JY; Kirova YM; Bidard FC Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):389-396. PubMed ID: 30291993 [TBL] [Abstract][Full Text] [Related]
14. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients. Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282 [TBL] [Abstract][Full Text] [Related]
15. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. Novoa Vargas A; Font López KC; Amador DD Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856 [TBL] [Abstract][Full Text] [Related]
16. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Sengupta S; Jordan VC Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493 [TBL] [Abstract][Full Text] [Related]
17. OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database. Hu K; He P; Peng Q; Zhong X; Deng L; Xie Y; Li J; Xu H; Lu D; Zheng H Breast Cancer; 2019 May; 26(3):339-348. PubMed ID: 30367358 [TBL] [Abstract][Full Text] [Related]
18. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Pachmann K; Clement JH; Schneider CP; Willen B; Camara O; Pachmann U; Höffken K Clin Chem Lab Med; 2005; 43(6):617-27. PubMed ID: 16006258 [TBL] [Abstract][Full Text] [Related]
19. Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients. Mäurer M; Pachmann K; Wendt T; Schott D; Wittig A Curr Oncol; 2021 Sep; 28(5):3507-3524. PubMed ID: 34590615 [TBL] [Abstract][Full Text] [Related]
20. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Howell SJ; Johnston SR; Howell A Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]